Cytopathology Diagnosis of Thyroid Nodules_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 平波

;

Corresponding?author：

Keywords：

甲狀腺結節; 細針穿刺; 細胞學檢查

DOI：

10.7507/1007-9424.20140259

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 平波. Cytopathology Diagnosis of Thyroid Nodules. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(9): 1070-1075. doi: 10.7507/1007-9424.20140259 Copy

1.	中華醫學會內分泌學分會, 中華醫學會外科學分會內分泌學組, 中國抗癌協會頭頸腫瘤專業委員會, 等. 甲狀腺結節和分化型甲狀腺癌診治指南[J]. 中華內分泌代謝雜志, 2012, 28(10):779-797.
2.	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
3.	Camargo R, Corigliano S, Friguglietti C, et al. Latin American thyroid society recommendations for the management of thyroid nodules[J]. Arq Bras Endocrinol Metabol, 2009, 53(9):1167-1175.
4.	Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules[J]. Endocr Pract, 2010, 16 Suppl 1:1-43.
5.	Paschke R, Hegedues L, Alexander E, et al. Thyroid nodule guidelines:agreement, disagreement and need for future research[J]. Nat Rev Endocrinol, 2011, 7(6):354-361.
6.	Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation[J]. Cancer, 2007, 111(6):508-516.
7.	Gharib H, Goellner JR, Johnson DA. Fine-needle aspiration cytology of the thyroid. A 12-year experience with 11000 biopsies[J]. Clin Lab Med, 1993, 13(3):699-709.
8.	Hamberger B, Gharib H, Melton LJ 3^rd, et al. Fine-needle aspiration biopsy of thyroid nodules.Impact on thyroid practice and cost of care[J]. Am J Med, 1982, 73(3):381-384.
9.	Ali SZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology:definitions, criteria and explanatory notes[M]. New York:Springer-Verlag New York Inc, 2009:1-166.
10.	Antic T, Taxy JB. Thyroid frozen section supplementary or unnecessary?[J]. Am J Surg Pathol, 2013, 37(2):282-286.
11.	Prades JM, Querat C, Dumollard JM, et al. Thyroid nodule surgery:predictive diagnostic value of fine-needle aspiration cytology and frozen section[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2013,[Epub ahead of print].
12.	Kahmke R, Lee WT, Puscas L, et al. Utility of intraoperative frozen sections during thyroid surgery[J]. Int J Otolaryngol, 2013, 2013:496138.
13.	張永俠, 張彬, 張智慧, 等. 甲狀腺結節細針穿刺細胞學檢查評估[J]. 中華耳鼻咽喉頭頸外科雜志, 2011, 46(11):892-896.
14.	田文, 羅晉. 中國與美國甲狀腺結節與分化型甲狀腺癌診治指南比較[J]. 中國實用外科雜志, 2013, 33(6):475-479.
15.	亞明宏. 2012年中國版《甲狀腺結節和分化型甲狀腺癌診治指南》解讀[J]. 臨床耳鼻咽喉頭頸外科雜志, 2013, 27(16):917-920.
16.	Hahn SY, Shin JH, Han BK, et al. Ultrasonography-guided core needle biopsy for the thyroid nodule:does the procedure hold any benefit for the diagnosis when fine-needle aspiration cytology analysis shows inconclusive results?[J]. Br J Radiol, 2013, 86(1025):20130007.
17.	Stangierski A, Wolinski K, Martin K, et al. Core needle biopsy of thyroid nodules-evaluation of diagnostic utility and pain experience[J]. Neuro Endocrinol Lett, 2013, 34(8):798-801.
18.	Na DG, Kim JH, Sung JY, et al. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology[J]. Thyroid, 2012, 22(5):468-475.
19.	Guidelines of the Papanicolaou Society of Cytopathology for the examination of fine-needle aspiration specimens from thyroid nodules. The Papanicolaou Society of Cytopathology Task Force on Standards of Practice[J]. Diagn Cytopathol, 1996, 15(1):84-89.
20.	Lobo C, Mcqueen A, Beale T, et al. The UK royal college of pathologists thyroid fine-needle aspiration diagnostic classification is a robust tool for the clinical management of abnormal thyroid nodules[J]. Acta Cytol, 2011, 55(6):499-506.
21.	Baloch ZW, Cibas ES, Clark DP, et al. The National Cancer Institute Thyroid fine needle aspiration state of the science conference:a summation[J]. Cytojournal, 2008, 5:6.
22.	Ali SZ, Cibas ES著, 楊斌, 薛德彬主譯. 甲狀腺細胞病理學Bethesda報告系統:定義、標準和注釋[M]. 北京:北京科學技術出版社, 2010:1-166.
23.	平波. 細針穿刺細胞學診斷甲狀腺癌價值及評價[J]. 中國實用外科雜志, 2011, 31(5):386-388.
24.	Cibas ES, Ali SZ;NCI Thyroid FNA State of the Science Conference. The Bethesda system for reporting thyroid cytopathology[J]. Am J Clin Pathol, 2009, 132(5):658-665.
25.	Olson MT, Clark DP, Erozan YS, et al. Spectrum of risk of malignancy in subcategories of‘atypia of undetermined significance’[J]. Acta Cytol, 2011, 55(6):518-525.
26.	British Thyroid Association, Royal College of Pathologists. Guidelines for reporting of thyroid cytology specimens[EB/OL]. 2009, http://www.rcpath.org/resources/pdf/g089guidanceonthereportingofthyroidcytologyfinal.pdf.
27.	Renshaw AA, Krane JF. Can changing the terminology for benign aspirates reduce the atypia of undetermined significance/follicular lesion of undetermined significance rate in thyroid fineneedle aspirates?[J]. Cancer Cytopathol, 2013, 121(4):175-178.
28.	Nishino M, Wang HH. Should the thyroid AUS/FLUS category be further stratified by malignancy risk?[J]. Cancer Cytopathol, 2014, 122(7):481-483.
29.	Cochand-Priollet B, Schmitt FC, T?tsch M, et al. The Bethesda terminology for reporting thyroid cytopathology:from theory to practice in Europe[J]. Acta Cytol, 2011, 55(6):507-511.
30.	Kocjan G, Chandra A, Cross PA, et al. The interobserver reproducibility of thyroid fine-needle aspiration using the UK royal college of pathologists' classification system[J]. Am J Clin Pathol, 2011, 135(6):852-859.
31.	Bongiovanni M, Spitale A, Faquin WC, et al. The Bethesda system for reporting thyroid cytopathology:a meta-analysis[J]. Acta Cytol, 2012, 56(4):333-339.
32.	Ohori NP, Schoedel KE. Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the Bethesda System for Reporting Thyroid Cytopathology:sources and recommendations[J]. Acta Cytol, 2011, 55(6):492-498.
33.	Ho AS, Sarti EE, Jain KS, et al. Malignancy rate in thyroid nodules classified as Bethesda category Ⅲ (AUS/FLUS)[J]. Thyroid, 2014, 24(5):832-839.
34.	Park HJ, Moon JH, Yom CK, et al. Thyroid "atypia of undetermined significance" with nuclear atypia has high rates of malignancy and BRAF mutation[J]. Cancer Cytopathol, 2014, 122(7):512-520.
35.	Xing M, Haugen BR, Schlumberger M. Progress in molecularbased management of differentiated thyroid cancer[J]. Lancet, 2013, 381(9871):1058-1069.
36.	Rossi ED, Raffaelli M, Mule' A, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid[J]. Histopathology, 2006, 48(7):795-800.
37.	Chu PG, Lau SK, Weiss LM. Keratin expression in endocrine organs and their neoplasms[J]. Endocr Pathol, 2009, 20(1):1-10.
38.	Das DK, Al-Waheeb SK, George SS, et al. Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma[J]. Diagn Cytopathol, 2014, 42(6):498-505.
39.	Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules:a prospective analysis of 1056 FNA samples[J]. J Clin Endocrinol Metab, 2011, 96(11):3390-3397.
40.	Mehta V, Nikiforov YE, Ferris RL. Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery[J]. Head Neck, 2013, 35(10):1499-1506.

1. 中華醫學會內分泌學分會, 中華醫學會外科學分會內分泌學組, 中國抗癌協會頭頸腫瘤專業委員會, 等. 甲狀腺結節和分化型甲狀腺癌診治指南[J]. 中華內分泌代謝雜志, 2012, 28(10):779-797.
2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
3. Camargo R, Corigliano S, Friguglietti C, et al. Latin American thyroid society recommendations for the management of thyroid nodules[J]. Arq Bras Endocrinol Metabol, 2009, 53(9):1167-1175.
4. Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules[J]. Endocr Pract, 2010, 16 Suppl 1:1-43.
5. Paschke R, Hegedues L, Alexander E, et al. Thyroid nodule guidelines:agreement, disagreement and need for future research[J]. Nat Rev Endocrinol, 2011, 7(6):354-361.
6. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation[J]. Cancer, 2007, 111(6):508-516.
7. Gharib H, Goellner JR, Johnson DA. Fine-needle aspiration cytology of the thyroid. A 12-year experience with 11000 biopsies[J]. Clin Lab Med, 1993, 13(3):699-709.
8. Hamberger B, Gharib H, Melton LJ 3^rd, et al. Fine-needle aspiration biopsy of thyroid nodules.Impact on thyroid practice and cost of care[J]. Am J Med, 1982, 73(3):381-384.
9. Ali SZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology:definitions, criteria and explanatory notes[M]. New York:Springer-Verlag New York Inc, 2009:1-166.
10. Antic T, Taxy JB. Thyroid frozen section supplementary or unnecessary?[J]. Am J Surg Pathol, 2013, 37(2):282-286.
11. Prades JM, Querat C, Dumollard JM, et al. Thyroid nodule surgery:predictive diagnostic value of fine-needle aspiration cytology and frozen section[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2013,[Epub ahead of print].
12. Kahmke R, Lee WT, Puscas L, et al. Utility of intraoperative frozen sections during thyroid surgery[J]. Int J Otolaryngol, 2013, 2013:496138.
13. 張永俠, 張彬, 張智慧, 等. 甲狀腺結節細針穿刺細胞學檢查評估[J]. 中華耳鼻咽喉頭頸外科雜志, 2011, 46(11):892-896.
14. 田文, 羅晉. 中國與美國甲狀腺結節與分化型甲狀腺癌診治指南比較[J]. 中國實用外科雜志, 2013, 33(6):475-479.
15. 亞明宏. 2012年中國版《甲狀腺結節和分化型甲狀腺癌診治指南》解讀[J]. 臨床耳鼻咽喉頭頸外科雜志, 2013, 27(16):917-920.
16. Hahn SY, Shin JH, Han BK, et al. Ultrasonography-guided core needle biopsy for the thyroid nodule:does the procedure hold any benefit for the diagnosis when fine-needle aspiration cytology analysis shows inconclusive results?[J]. Br J Radiol, 2013, 86(1025):20130007.
17. Stangierski A, Wolinski K, Martin K, et al. Core needle biopsy of thyroid nodules-evaluation of diagnostic utility and pain experience[J]. Neuro Endocrinol Lett, 2013, 34(8):798-801.
18. Na DG, Kim JH, Sung JY, et al. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology[J]. Thyroid, 2012, 22(5):468-475.
19. Guidelines of the Papanicolaou Society of Cytopathology for the examination of fine-needle aspiration specimens from thyroid nodules. The Papanicolaou Society of Cytopathology Task Force on Standards of Practice[J]. Diagn Cytopathol, 1996, 15(1):84-89.
20. Lobo C, Mcqueen A, Beale T, et al. The UK royal college of pathologists thyroid fine-needle aspiration diagnostic classification is a robust tool for the clinical management of abnormal thyroid nodules[J]. Acta Cytol, 2011, 55(6):499-506.
21. Baloch ZW, Cibas ES, Clark DP, et al. The National Cancer Institute Thyroid fine needle aspiration state of the science conference:a summation[J]. Cytojournal, 2008, 5:6.
22. Ali SZ, Cibas ES著, 楊斌, 薛德彬主譯. 甲狀腺細胞病理學Bethesda報告系統:定義、標準和注釋[M]. 北京:北京科學技術出版社, 2010:1-166.
23. 平波. 細針穿刺細胞學診斷甲狀腺癌價值及評價[J]. 中國實用外科雜志, 2011, 31(5):386-388.
24. Cibas ES, Ali SZ;NCI Thyroid FNA State of the Science Conference. The Bethesda system for reporting thyroid cytopathology[J]. Am J Clin Pathol, 2009, 132(5):658-665.
25. Olson MT, Clark DP, Erozan YS, et al. Spectrum of risk of malignancy in subcategories of‘atypia of undetermined significance’[J]. Acta Cytol, 2011, 55(6):518-525.
26. British Thyroid Association, Royal College of Pathologists. Guidelines for reporting of thyroid cytology specimens[EB/OL]. 2009, http://www.rcpath.org/resources/pdf/g089guidanceonthereportingofthyroidcytologyfinal.pdf.
27. Renshaw AA, Krane JF. Can changing the terminology for benign aspirates reduce the atypia of undetermined significance/follicular lesion of undetermined significance rate in thyroid fineneedle aspirates?[J]. Cancer Cytopathol, 2013, 121(4):175-178.
28. Nishino M, Wang HH. Should the thyroid AUS/FLUS category be further stratified by malignancy risk?[J]. Cancer Cytopathol, 2014, 122(7):481-483.
29. Cochand-Priollet B, Schmitt FC, T?tsch M, et al. The Bethesda terminology for reporting thyroid cytopathology:from theory to practice in Europe[J]. Acta Cytol, 2011, 55(6):507-511.
30. Kocjan G, Chandra A, Cross PA, et al. The interobserver reproducibility of thyroid fine-needle aspiration using the UK royal college of pathologists' classification system[J]. Am J Clin Pathol, 2011, 135(6):852-859.
31. Bongiovanni M, Spitale A, Faquin WC, et al. The Bethesda system for reporting thyroid cytopathology:a meta-analysis[J]. Acta Cytol, 2012, 56(4):333-339.
32. Ohori NP, Schoedel KE. Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the Bethesda System for Reporting Thyroid Cytopathology:sources and recommendations[J]. Acta Cytol, 2011, 55(6):492-498.
33. Ho AS, Sarti EE, Jain KS, et al. Malignancy rate in thyroid nodules classified as Bethesda category Ⅲ (AUS/FLUS)[J]. Thyroid, 2014, 24(5):832-839.
34. Park HJ, Moon JH, Yom CK, et al. Thyroid "atypia of undetermined significance" with nuclear atypia has high rates of malignancy and BRAF mutation[J]. Cancer Cytopathol, 2014, 122(7):512-520.
35. Xing M, Haugen BR, Schlumberger M. Progress in molecularbased management of differentiated thyroid cancer[J]. Lancet, 2013, 381(9871):1058-1069.
36. Rossi ED, Raffaelli M, Mule' A, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid[J]. Histopathology, 2006, 48(7):795-800.
37. Chu PG, Lau SK, Weiss LM. Keratin expression in endocrine organs and their neoplasms[J]. Endocr Pathol, 2009, 20(1):1-10.
38. Das DK, Al-Waheeb SK, George SS, et al. Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma[J]. Diagn Cytopathol, 2014, 42(6):498-505.
39. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules:a prospective analysis of 1056 FNA samples[J]. J Clin Endocrinol Metab, 2011, 96(11):3390-3397.
40. Mehta V, Nikiforov YE, Ferris RL. Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery[J]. Head Neck, 2013, 35(10):1499-1506.

Previous Article
直腸癌伴巨大轉移性卵巢癌1例報道
Next Article
The Bethesda System for Reporting Thyroid Cytopathology: A Single-Center Experience of 2 257 Thyroid Nodules

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Cytopathology Diagnosis of Thyroid Nodules

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content